Aleksandr Vasiliev

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +6

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama et al. · The Lancet · 2025 · 47 citations · Full text

Medicine, Oncology, Urology +13

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga et al. · The Lancet Oncology · 2023 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Nizar M. Tannir, Maria Nirvana Formiga, Konstantin Penkov et al. · Journal of Clinical Oncology · 2024 · 24 citations

Medicine, Immunology, Oncology +17